Compare FE & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FE | GEHC |
|---|---|---|
| Founded | 1996 | 1892 |
| Country | United States | United States |
| Employees | N/A | 54000 |
| Industry | Electric Utilities: Central | Computer Software: Prepackaged Software |
| Sector | Utilities | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1B | 27.9B |
| IPO Year | 2005 | 2022 |
| Metric | FE | GEHC |
|---|---|---|
| Price | $49.54 | $61.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $51.46 | ★ $88.38 |
| AVG Volume (30 Days) | 3.0M | ★ 4.3M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.80% | 0.24% |
| EPS Growth | 3.53 | ★ 4.84 |
| EPS | 0.70 | ★ 0.85 |
| Revenue | $15,090,000,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $4.34 | $7.12 |
| Revenue Next Year | $3.98 | $4.45 |
| P/E Ratio | ★ $70.69 | $72.93 |
| Revenue Growth | ★ 12.01 | 4.84 |
| 52 Week Low | $41.30 | $58.75 |
| 52 Week High | $52.34 | $89.77 |
| Indicator | FE | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 58.88 | 39.55 |
| Support Level | $48.22 | $60.17 |
| Resistance Level | $52.01 | $65.72 |
| Average True Range (ATR) | 0.83 | 1.80 |
| MACD | 0.04 | -0.38 |
| Stochastic Oscillator | 70.89 | 6.93 |
FirstEnergy is an investor-owned holding company with operations across five mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).